In a large French study, bariatric surgery was associated with a significant reduction in incidence of esophageal and gastric cancer as well as overall mortality.
New data show that survival outcomes were best when surgery came 6–8 weeks after neoadjuvant chemotherapy. The study was published as a preprint and has not yet been peer reviewed.
With the last update published in 2017, current consensus, released in August 2022, covers most of the latest progress made in the management of the infection.